DelveInsight’s “Chronic Kidney Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Chronic Kidney Disease pipeline landscapes.
The report comprises Chronic Kidney Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Kidney Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Kidney Disease pipeline products.
Some of the key takeaways from the Chronic Kidney Disease Pipeline Report:
- Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as GlaxoSmithKline, Akebia Therapeutics, FibroGen/ Astellas Pharma/ AstraZeneca, Boehringer Ingelheim, Astra Zeneca, Tricida, Reata Pharmaceuticals, Corvidia Therapeutics, etc., are developing therapies for the treatment of Chronic Kidney Disease.
- Emerging therapies such as Daprodustat, Vadadustatm, Roxadustat, Empagliflozin, Dapagliflozin, Veverimer, Bardoxolone Methyl, Ziltivekimab, are expected to have a significant impact on the Chronic Kidney Disease market in the coming years.
Get an overview of pipeline landscape @ Chronic Kidney Disease Clinical Trials Analysis
Chronic kidney disease (CKD) means your kidneys are damaged and can’t filter blood the way they should. The disease is called “chronic” because the damage to your kidneys happens slowly over a long period of time. This damage can cause wastes to build up in your body.
- Daprodustat by GlaxoSmithKline
- Vadadustat by Akebia Therapeutics
- Roxadustat by FibroGen/ Astellas Pharma/ AstraZeneca
- Empagliflozin by Boehringer Ingelheim
- Dapagliflozin by Astra Zeneca
- Veverimer by Tricida
- Bardoxolone Methyl by Reata Pharmaceuticals
- Ziltivekimab by Corvidia Therapeutics
- And others.
Scope of Chronic Kidney Disease Pipeline Drug Insight
- Coverage: Global
- Major Players: GlaxoSmithKline, Akebia Therapeutics, FibroGen/ Astellas Pharma/ AstraZeneca, Boehringer Ingelheim, Astra Zeneca, Tricida, Reata Pharmaceuticals, Corvidia Therapeutics, and others.
- Pipeline Therapies: Daprodustat, Vadadustatm, Roxadustat, Empagliflozin, Dapagliflozin, Veverimer, Bardoxolone Methyl, Ziltivekimab, and others.
Table of Contents
|1||Chronic Kidney Disease Report Introduction|
|2||Chronic Kidney Disease Executive Summary|
|3||Chronic Kidney Disease Overview|
|4||Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment|
|5||Chronic Kidney Disease Pipeline Therapeutics|
|6||Chronic Kidney Disease Late Stage Products (Phase II/III)|
|7||Chronic Kidney Disease Mid Stage Products (Phase II)|
|8||Chronic Kidney Disease Early Stage Products (Phase I)|
|9||Chronic Kidney Disease Preclinical Stage Products|
|10||Chronic Kidney Disease Therapeutics Assessment|
|11||Chronic Kidney Disease Inactive Products|
|12||Company-University Collaborations (Licensing/Partnering) Analysis|
|13||Chronic Kidney Disease Key Companies|
|14||Chronic Kidney Disease Key Products|
|15||Chronic Kidney Disease Unmet Needs|
|16||Chronic Kidney Disease Market Drivers and Barriers|
|17||Chronic Kidney Disease Future Perspectives and Conclusion|
|18||Chronic Kidney Disease Analyst Views|
DelveInsight’s “Chronic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s ‘Chronic Kidney Disease – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Kidney Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.